LLY

1,138.2

-1.02%↓

JNJ

238.57

+0.62%↑

ABBV

226.19

+0.18%↑

UNH

404.99

-1.5%↓

MRK

118.66

-1.28%↓

LLY

1,138.2

-1.02%↓

JNJ

238.57

+0.62%↑

ABBV

226.19

+0.18%↑

UNH

404.99

-1.5%↓

MRK

118.66

-1.28%↓

LLY

1,138.2

-1.02%↓

JNJ

238.57

+0.62%↑

ABBV

226.19

+0.18%↑

UNH

404.99

-1.5%↓

MRK

118.66

-1.28%↓

LLY

1,138.2

-1.02%↓

JNJ

238.57

+0.62%↑

ABBV

226.19

+0.18%↑

UNH

404.99

-1.5%↓

MRK

118.66

-1.28%↓

LLY

1,138.2

-1.02%↓

JNJ

238.57

+0.62%↑

ABBV

226.19

+0.18%↑

UNH

404.99

-1.5%↓

MRK

118.66

-1.28%↓

Home・Listă Acțiuni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Deschisă

SectorSănătate

23.43 4.88

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

22.23

Maxim

23.97

Indicatori cheie
By Trading Economics
Venit	-29M -11M
Vânzări	-24M 105M
EPS	-0.09
Marjă de profit	-10.717
Angajați	354
EBITDA	-31M -8.5M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+52.83% upside

Dividende
By Dow Jones
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-282M 2.7B
Deschiderea anterioară	18.55
Închiderea anterioară	23.43

Sentimentul știrilor

By Acuity

50%

153 / 344 Clasament în Healthcare

Arcutis Biotherapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 iun. 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 iun. 2026, 23:45 UTC

Achiziții, Fuziuni, Preluări

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 iun. 2026, 23:44 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 iun. 2026, 23:44 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 iun. 2026, 23:43 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 iun. 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 iun. 2026, 22:06 UTC

Achiziții, Fuziuni, Preluări

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 iun. 2026, 20:51 UTC

Câștiguri

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 iun. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iun. 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 iun. 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 iun. 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 iun. 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 iun. 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 iun. 2026, 18:52 UTC

Achiziții, Fuziuni, Preluări

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 iun. 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 iun. 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 iun. 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 iun. 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 iun. 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 iun. 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

9 iun. 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 iun. 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparație

Modificare preț

Arcutis Biotherapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

52.83% sus

Prognoză pe 12 luni

Medie 34.83 USD 52.83%

Maxim 36 USD

Minim 34 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Arcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

153 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.